neurology7.435 min read
Mild Heart Dysfunction Linked to Hidden Brain Changes and Memory Loss
4 days ago•Source: News-Medical
Neurology News
The latest neurology stories, summarized by AI
Featured Neurology Stories
View original source
5.2 min•1 year ago
Creatine Shows Promise in Alzheimer's Treatment and Brain Health
A small pilot study suggests that creatine monohydrate supplements may increase serum and brain creatine levels and show positive trends in cognition among Alzheimer's patients, but further research is needed to confirm efficacy.
More Top Stories
2
Unveiling the Uncommon Syndrome Linked to COVID Vaccines
Medpage Today•2 years ago
3
Unraveling the Impact of Long COVID on the Brain
Medpage Today•2 years ago
More Neurology Stories
Physician Group's New Statement on Determining Death
The American College of Physicians (ACP) has issued a new position paper on the determination of death, advocating for a single word revision to the Uniform Determination of Death Act (UDDA). The ACP supports replacing the word "irreversible" with "permanent" in the UDDA to define circulatory determination of death, while maintaining separate cardiorespiratory and neurologic standards. The ACP also emphasizes the importance of aligning medical testing with standards of determining death and separating issues about determination of death from organ transplantation. The ACP's position paper aims to provide clarity and education on the standards and ethics surrounding the determination of death.
Limited Eligibility for Lecanemab in Early Alzheimer's Patients
Only a small percentage of individuals with early Alzheimer's disease meet the eligibility criteria for the anti-amyloid monoclonal antibody treatments lecanemab and aducanumab, according to data from the Mayo Clinic Study of Aging. The study found that out of 237 participants with mild cognitive impairment or mild dementia and increased brain amyloid, only 8% qualified for a lecanemab trial and 5.1% qualified for an aducanumab trial. The researchers noted that the strict criteria, which include chronic health conditions and brain scan abnormalities, limit the number of eligible candidates. Further research is needed to assess the safety and efficacy of these treatments in larger and more diverse populations before they can be widely available to Alzheimer's patients.
"Insights into Long COVID: Immune Dysregulation, Genetic Impact, and CBT Benefits"
A small cohort study conducted by the National Institute of Neurological Disorders and Stroke (NINDS) of the NIH in Bethesda, Maryland, found that people with long COVID neurologic symptoms had broad immune dysregulation in their cerebrospinal fluid (CSF), with lower levels of CD4+ and CD8+ T cells and increased B cells and other types of immune cells. Autonomic testing also showed dysfunction. The findings suggest that immune dysregulation may play a role in mediating long COVID and call for further investigations to confirm these changes and evaluate the role of immunomodulatory agents in clinical trials.
COVID-19 Linked to Neurological Disorders and Increased MS Disability.
Patients with functional neurological disorder (FND) after COVID-19 infection had different symptoms than people with FND after COVID-19 vaccines, according to a retrospective study. Those with FND after COVID-19 vaccination more closely resembled classic FND, while those with post-COVID FND tended to be older, had more insidious onset, and had higher disability. The findings point to a need to consider FND when diagnosing patients with post-COVID neurologic symptoms.